Navigation Links
RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
Date:2/8/2013

SEOUL, South Korea, Feb. 8, 2013 /PRNewswire/ -- RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III assessing the company's RNL-Astrostem™ stem cell drug in patients with cerebral palsy. The purpose of this study is to assess conclusive efficacy of stem cells for the treatment of cerebral palsy in 45 subjects over 11 months.  The study is to be conducted through Kyung Hee University Hospital at Gangdong and THE Bethesda Hospital.

RNL-Astrostem™, has already completed a phase I trial to assure safety, including tests to rule out toxicity or tumorigenicity.  This trial was conducted at the Seoul National University's Clinical Research Institute.  In addition, the phase I study has confirmed the safety of stem cells infused by IV, as published in a leading peer-reviewed journal, Stem Cells and Development ("Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans," February 2011). In the course of successful safety trials, scientists found significant evidence suggesting the potential for efficacy of stem cells in treatment of cerebral palsy. In addition, a case report with obvious result of improvement was published in another internationally renowned journal. RNL BIO believes that with successful trials and approval of the KFDA, it will be possible to commercialize RNL-Astrostem™ by 2014, revolutionizing the possibility to cure this incurable disease of children, which can only be managed with current technologies.

Cerebral Palsy is caused by non-progressive brain damage from single or multiple defect(s) on the nerve/muscular system and results in disorder in motion and sensory integration. According to Health Insurance Review and Assessment Service, the prevalence of cerebral palsy is 3.5 per 1000 male to 2.8 per 1000 female children, averaged at 3.2 per 1000 children, which is expected to increase due to reduction of premature death.

In the clinical study investigators employ a variety of methods to assess efficacy: K-ABC: Kaufman Assessment Battery for Children, Gross Motor Function Measure, (GMFM), box and block test, Modified Asworth Scale, MAS, finger tapping test, Brain SPECT and MRI.

Dr. JC Ra, president of RNL BIO Stem Cell Technology Institute, said, "It is our mission to find cures for incurable diseases, such as the terrible pediatric curse of cerebral palsy, through autologous stem cell technology." 

About RNL BIO

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell technologies. RNL has completed one phase I trial for spinal cord injury and one Phase II clinical trial for Osteoarthritis and is near to the completion of Buerger's Disease trial. RNL has been a supporter of UN Global Compact's free program to work with children who suffer from cerebral palsy, as major sponsor of the Bethesda Life Foundation. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.


'/>"/>
SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
2. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
3. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
6. Lotus Pharmaceutical Company Inc. Filed Its Abbreviated New Drug Application (ANDA) Containing a Paragraph IV Certification for a Generic Version of Xenical(R) with the U.S. Food & Drug Administration (FDA)
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):